An overview of prostate cancer (PCa) diagnosis: Potential role of miRNAs

Bilal, Muhammad; Javaid, Aqsa; Amjad, Farhat; Youssif, Tamer Abou; Afzal, Samia

doi:10.1016/j.tranon.2022.101542

Cited by 20 publications

(11 citation statements)

References 160 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study revealed that miR-153 is in fact overexpressed in PC tissues. Our results are consistent with Wu et al, who identified miR-153 to be overexpressed in PC and showed that miR-153 plays a crucial role in increased proliferation of human PC cells and via a process of miRNA-mediated suppression of PTEN expression in PC cells [ 8 ].…”

Section: Discussionsupporting

confidence: 93%

“…Aberrant miRNAs expression has been identified in a variety of malignant tumors, with recent evidence suggesting that miRNAs function as tumor suppressor genes and/or oncogenes [ 7 ]. Recent studies have various miRNAs expression profiles in PC tissues [ [8] , [9] , [10] , [11] ]. MiR-153 was found to be downregulated in various cancers, such as breast cancer (BC), gastric cancer (GC) and oral cancer (OC) [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The potential of miR-153 as aggressive prostate cancer biomarker

Gilyazova

Ivanova²,

Sinelnikov³

et al. 2023

Non-coding RNA Research

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

The potential of miR-153 as aggressive prostate cancer biomarker

Gilyazova

Ivanova²,

Sinelnikov³

et al. 2023

Non-coding RNA Research

View full text Add to dashboard Cite

“…Early detection of PC improves overall patient survival in low-risk patients, but has no effect on the survival of patients with metastatic cancer [ 149 , 150 , 165 ]. Since the management strategy for low-risk patients is active monitoring, careful patient selection and accuracy in risk assessment require new, more precise and more specific biomarkers, since randomized controlled trials have shown that PSA screening has no effect on overall mortality or prostate cancer-caused mortality [ 166 ]. According to a meta-analysis of five randomized controlled trials that encompassed a total of 721,718 men, screening is likely to result in a minor decrease in specific mortality over a 10-year period.…”

Section: Methods For Diagnosing Prostate Cancermentioning

confidence: 99%

Prostate Cancer: Genetics, Epigenetics and the Need for Immunological Biomarkers

Rafikova

Gilyazova

Enikeeva

et al. 2023

IJMS

View full text Add to dashboard Cite

Epidemiological data highlight prostate cancer as a significant global health issue, with high incidence and substantial impact on patients’ quality of life. The prevalence of this disease is associated with various factors, including age, heredity, and race. Recent research in prostate cancer genetics has identified several genetic variants that may be associated with an increased risk of developing the disease. However, despite the significance of these findings, genetic markers for prostate cancer are not currently utilized in clinical practice as reliable indicators of the disease. In addition to genetics, epigenetic alterations also play a crucial role in prostate cancer development. Aberrant DNA methylation, changes in chromatin structure, and microRNA (miRNA) expression are major epigenetic events that influence oncogenesis. Existing markers for prostate cancer, such as prostate-specific antigen (PSA), have limitations in terms of sensitivity and specificity. The cost of testing, follow-up procedures, and treatment for false-positive results and overdiagnosis contributes to the overall healthcare expenditure. Improving the effectiveness of prostate cancer diagnosis and prognosis requires either narrowing the risk group by identifying new genetic factors or enhancing the sensitivity and specificity of existing markers. Immunological biomarkers (both circulating and intra-tumoral), including markers of immune response and immune dysfunction, represent a potentially useful area of research for enhancing the diagnosis and prognosis of prostate cancer. Our review emphasizes the need for developing novel immunological biomarkers to improve the diagnosis, prognosis, and management of prostate cancer. We highlight the most recent achievements in the identification of biomarkers provided by circulating monocytes and tumor-associated macrophages (TAMs). We highlight that monocyte-derived and TAM-derived biomarkers can enable to establish the missing links between genetic predisposition, hormonal metabolism and immune responses in prostate cancer.

show abstract

“…The Gleason score establishes the proper risk assessment and treatment selection through tissue biopsy [ 24 ]. Other non-invasive procedures are used for diagnosing and monitoring PC patients, including the Ki67 score, image analysis, and urine and blood biomarkers determination [ 25 ]. PSA is one the most important biomarkers for PC.…”

Section: Introductionmentioning

confidence: 99%

Microfluidic Platform Integrated with Carbon Nanofibers-Decorated Gold Nanoporous Sensing Device for Serum PSA Quantification

et al. 2023

View full text Add to dashboard Cite

Prostate cancer is a disease with a high incidence and mortality rate in men worldwide. Serum prostate-specific antigens (PSA) are the main circulating biomarker for this disease in clinical practices. In this work, we present a portable and reusable microfluidic device for PSA quantification. This device comprises a polymethyl methacrylate microfluidic platform coupled with electrochemical detection. The platinum working microelectrode was positioned in the outflow region of the microchannel and was modified with carbon nanofibers (CNF)-decorated gold nanoporous (GNP) structures by the dynamic hydrogen bubble template method, through the simultaneous electrodeposition of metal precursors in the presence of CNF. CNF/GNP structures exhibit attractive properties, such as a large surface to volume ratio, which increases the antibody’s immobilization capacity and the electroactive area. CNFs/GNP structures were characterized by scanning electron microscopy, energy dispersive spectrometry, and cyclic voltammetry. Anti-PSA antibodies and HRP were employed for the immune-electrochemical reaction. The detection limit for the device was 5 pg mL−1, with a linear range from 0.01 to 50 ng mL−1. The coefficients of variation within and between assays were lower than 4.40%, and 6.15%, respectively. Additionally, its clinical performance was tested in serum from 30 prostate cancer patients. This novel device was a sensitive, selective, portable, and reusable tool for the serological diagnosis and monitoring of prostate cancer.

show abstract

An overview of prostate cancer (PCa) diagnosis: Potential role of miRNAs

Cited by 20 publications

References 160 publications

The potential of miR-153 as aggressive prostate cancer biomarker

The potential of miR-153 as aggressive prostate cancer biomarker

Prostate Cancer: Genetics, Epigenetics and the Need for Immunological Biomarkers

Microfluidic Platform Integrated with Carbon Nanofibers-Decorated Gold Nanoporous Sensing Device for Serum PSA Quantification

Contact Info

Product

Resources

About